Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of different conbercept injection regimens in the treatment of choroidal neovascularization in pathological myopia: a retrospective study

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the clinical efficacy of conbercept 1 + pro re nata (PRN) (i.e., reinjection as needed after one injection) and 3 + PRN (reinjection as needed after 3 months of injection) regimens in choroidal neovascularization secondary to pathological myopia (PM-CNV).

Methods

From 06/2019 to 06/2020, 65 patients (65 eyes) confirmed with PM-CNV were included in this retrospective study. Intravitreal injection of 0.5 mg conbercept was conducted either with the 1 + PRN or 3 + PRN strategy. Patients were followed up for 12 months. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), CNV lesion leakage area, the number of injections, and postoperative adverse reactions were observed.

Results

The mean age of the patients was 42.10 ± 4.69 years, and the average diopter was − 11.26 ± 2.97D. The BCVA at month 3 in the 3 + PRN (n = 30) group was lower than in the 1 + PRN (n = 35) group (P < 0.001). The CRT at month 3 in the 3 + PRN group was lower than in the 1 + PRN group (P < 0.001). After 12 months, there were no differences in the BCVA and CRT between the two groups (P > 0.05). The number of injections was less in 1 + PRN than in 3 + PRN (2.14 ± 1.06 vs. 3.37 ± 0.76, P < 0.001) at 12 months. No serious treatment-related ocular complications or serious systemic adverse events were found.

Conclusion

The 1 + PRN and 3 + PRN strategies of intravitreal injection of conbercept are effective in treating PM-CNV. The 1 + PRN regimen required fewer injections, and it might be more suitable for the treatment of PM-CNV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ohno-Matsui K, Kawasaki R, Jonas JB, Cheung CM, Saw SM, Verhoeven VJ, Klaver CC, Moriyama M, Shinohara K, Kawasaki Y, Yamazaki M, Meuer S, Ishibashi T, Yasuda M, Yamashita H, Sugano A, Wang JJ, Mitchell P, Wong TY (2015) International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol 159(5):877–83.e7. https://doi.org/10.1016/j.ajo.2015.01.022

    Article  PubMed  Google Scholar 

  2. Williams KM, Bertelsen G, Cumberland P, Wolfram C, Verhoeven VJ, Anastasopoulos E, Buitendijk GH, Cougnard-Grégoire A, Creuzot-Garcher C, Erke MG, Hogg R, Höhn R, Hysi P, Khawaja AP, Korobelnik JF, Ried J, Vingerling JR, Bron A, Dartigues JF, Fletcher A, Hofman A, Kuijpers RW, Luben RN, Oxele K, Topouzis F, von Hanno T, Mirshahi A, Foster PJ, van Duijn CM, Pfeiffer N, Delcourt C, Klaver CC, Rahi J, Hammond CJ (2015) Increasing prevalence of myopia in europe and the impact of education. Ophthalmology 122(7):1489–1497. https://doi.org/10.1016/j.ophtha.2015.03.018

    Article  PubMed  Google Scholar 

  3. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M (2003) Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110(7):1297–1305. https://doi.org/10.1016/s0161-6420(03)00461-5

    Article  PubMed  Google Scholar 

  4. Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, Tokoro T, Mochizuki M (2003) Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 87(5):570–573. https://doi.org/10.1136/bjo.87.5.570

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Zhu Y, Zhang T, Xu G, Peng L (2016) Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 12(12):Cd011160. https://doi.org/10.1002/14651858.CD011160.pub2

  6. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141(3):456–462. https://doi.org/10.1016/j.ajo.2005.10.012

    Article  CAS  PubMed  Google Scholar 

  7. Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM (2018) Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res 63:92–106. https://doi.org/10.1016/j.preteyeres.2017.10.005

  8. Kasahara K, Moriyama M, Morohoshi K, Yoshida T, Simada N, Nagaoka N, Yokoi T, Shinohara K, Kaneko Y, Suga M, Ohno-Matsui K (2017) Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia. Retina 37(6):1055–1064. https://doi.org/10.1097/iae.0000000000001313

    Article  CAS  PubMed  Google Scholar 

  9. Tufail A, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Cole M, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Yang Y, Andrews C, Brittain C, Osborne A (2013) Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond) 27(6):709–715. https://doi.org/10.1038/eye.2013.8

    Article  CAS  PubMed  Google Scholar 

  10. Cheung CMG, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M, Mitchell P, Ohno-Matsui K, Chen SJ, Wolf S, Wong TY (2017) Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology 124(11):1690–1711. https://doi.org/10.1016/j.ophtha.2017.04.028

    Article  PubMed  Google Scholar 

  11. Wang E, Chen Y (2013) Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 33(7):1375–1392. https://doi.org/10.1097/IAE.0b013e31827d260a

    Article  CAS  PubMed  Google Scholar 

  12. Calvo-González C, Reche-Frutos J, Fernández-Vigo JI, Sáenz-Francés F, Fernández-Pérez C, García-Feijóo J (2017) Long-term outcomes of two different initial dosing regimens of intravitreal Ranibizumab used to treat myopic choroidal neovascularization. Ophthalmologica 238(4):196–204. https://doi.org/10.1159/000478030

    Article  CAS  PubMed  Google Scholar 

  13. Kung YH, Wu TT, Huang YH (2014) One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol 92(8):e615–e620. https://doi.org/10.1111/aos.12457

    Article  CAS  PubMed  Google Scholar 

  14. Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, Stemper B, Asmus F, Zeitz O, Ishibashi T (2015) Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122(6):1220–1227. https://doi.org/10.1016/j.ophtha.2015.01.025

    Article  PubMed  Google Scholar 

  15. Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B, Li H (2009) The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 26(1):204–210. https://doi.org/10.1007/s11095-008-9718-9

    Article  CAS  PubMed  Google Scholar 

  16. Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, Luo D, Ke X (2014) Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121(9):1740–1747. https://doi.org/10.1016/j.ophtha.2014.03.026

    Article  PubMed  Google Scholar 

  17. Liu K, Wang H, He W, Ye J, Song Y, Wang Y, Liu X, Wu Z, Chen S, Fan K, Liu Y, Zhang F, Li Z, Liu L, Zhang J, Zhang X, Ye J, Liang X, Li X, Ke X, Wu Q, Li J, Tao S, Wang X, Rosenfeld P, Heier JS, Kaiser P, Xu X (2021) Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2020-318690

    Article  PubMed  Google Scholar 

  18. Yan M, Huang Z, Lian HY, Song YP, Chen X (2019) Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol 97(5):e813–e814. https://doi.org/10.1111/aos.13632

    Article  PubMed  Google Scholar 

  19. Nie X, Wang Y, Yi H, Qiao Y (2021) Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China: intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. BMC Ophthalmol 21(1):116. https://doi.org/10.1186/s12886-021-01877-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Keane PA, Liakopoulos S, Chang KT, Heussen FM, Ongchin SC, Walsh AC, Sadda SR (2008) Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol 92(8):1081–1085. https://doi.org/10.1136/bjo.2008.138891

    Article  CAS  PubMed  Google Scholar 

  21. Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ (2021) Risk of systemic adverse events after intravitreal bevacizumab, Ranibizumab, and Aflibercept in routine clinical practice. Ophthalmology 128(3):417–424. https://doi.org/10.1016/j.ophtha.2020.07.062

    Article  PubMed  Google Scholar 

  22. Cho HJ, Yoo SG, Kim HS, Kim JH, Kim CG, Lee TG, Kim JW (2015) Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol 159(2):285–92.e1. https://doi.org/10.1016/j.ajo.2014.10.035

    Article  CAS  PubMed  Google Scholar 

  23. Schütze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U (2015) Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol 159(6):1100-1114.e1. https://doi.org/10.1016/j.ajo.2015.02.020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121(3):682–92.e2. https://doi.org/10.1016/j.ophtha.2013.10.023

    Article  PubMed  Google Scholar 

  25. Lu X, Sun X (2015) Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther 9:2311–2320. https://doi.org/10.2147/dddt.S67536

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Yao TT, Jin XL, Yang Y, Wang YX, Zhou YL, He FL, Wang ZY (2020) Intraocular pharmacokinetics and safety of subretinal injection compared with intravitreal application of conbercept in vitrectomized rabbit eyes. J Ophthalmol 2020:2674780. https://doi.org/10.1155/2020/2674780

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Author notes

  1. Bin Gong and Yuxia Bo contributed equally to this work.

Authors and Affiliations

  1. Department of Ophthalmology, Jinan 2Nd People’s Hospital, Jinan, 250001, China

    Bin Gong, Peng Zhang & Lei Gao

  2. Department of Ophthalmology, Wucheng Hospital of Traditional Chinese Medicine, Dezhou, 253300, China

    Yuxia Bo

  3. Department of Ophthalmology, Shandong Second Provincial General Hospital, Jinan, 250299, China

    Jing Wang

Authors
  1. Bin Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuxia Bo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

None.

Corresponding authors

Correspondence to Jing Wang or Lei Gao.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Ethical approval

The present study was reviewed and approved by the Institutional Review Board of Jinan 2nd People's Hospital (approval number: [2019] 018) and was conducted in compliance with the principles of the Declaration of Helsinki.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent to publish

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gong, B., Bo, Y., Zhang, P. et al. Efficacy and safety of different conbercept injection regimens in the treatment of choroidal neovascularization in pathological myopia: a retrospective study. Int Ophthalmol 43, 4079–4086 (2023). https://doi.org/10.1007/s10792-023-02825-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-023-02825-9

Keywords

Search

Navigation